APOE and Alzheimer disease: In presymptomatic APOE-ε4 carriers, enhanced gray-matter atrophy, greater β-amyloid deposition and diminished cerebral glucose metabolism in the same brain regions as AD patients are seen, although these findings are not universal [3]–[8].